

Percutaneous tricuspid valve repair using MitraClip® for the treatment of severe tricuspid valve regurgitation in a patient with congenitally corrected transposition of the great arteries

J. P. van Melle¹ · R. Schurer¹ · M. Willemsen¹ · E. S. Hoendermis¹ · A. F. M. van den Heuvel¹

Published online: 13 July 2016

© The Author(s) 2016. This article is available at SpringerLink with Open Access

In selected patients, mitral valve repair using MitraClip® (Abbott, USA) is a relatively safe and well-tolerated treatment for significant mitral regurgitation [1–3]. We describe a 56-year-old female with congenitally corrected transposition of the great arteries (ccTGA) and dextrocardia (Fig. 1a) with recurrent episodes of heart failure caused by a combination of systemic (right) ventricular failure and tricuspid valve regurgitation (Fig. 1b). ccTGA is a rare congenital heart defect with discordance at both the atrioventricular and the ventriculoarterial level. In 20 % of the patients dextrocardia exists. Moderate to severe tricuspid valve regurgitation has a clear impact on cardiac prognosis [4]. We performed a percutaneous tricuspid valve repair using

MitraClip® in 2014 (off-label use) (Fig. 1c). Six months after valve clipping, the tricuspid regurgitation was mild and there was an important reduction in heart failure symptoms. Mitral clipping may be feasible in selected patients with ccTGA. As far as we know, this is the first percutaneous tricuspid valve repair using MitraClip® in a patient with ccTGA and dextrocardia.

Acknowledgements We thank Frank Jagers (Abbott Vascular Structural Heart) for the peri-procedural assistance.

Funding none.

Conflict of interest J.P. van Melle, R. Schurer, M. Willemsen, E.S. Hoendermis and A.F.M. van den Heuvel state that there are no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a

✉ J. P. van Melle
j.p.van.melle@umcg.nl

¹ Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands




Fig. 1 Magnetic resonance imaging showing a ccTGA diagnosis. The hypertrabeculated system ventricle is a morphological right ventricle (a). Echocardiographic images showing severe tricuspid regurgitation pre-MitraClip® (b). Fluoroscopy showing the delivery system and clip. Note the dextrocardia with apex to the right (c)

link to the Creative Commons license, and indicate if changes were made.

References

1. Beigel R, Wunderlich NC, Kar S, Siegel RJ. The evolution of percutaneous mitral valve repair therapy: lessons learned and implications for patient selection. *J Am Coll Cardiol*. 2014;64:2688–700.
2. Yong ZY, Bouma BJ, Koch KT, Baan J. Immediate reduction of mitral regurgitation by percutaneous mitral valve repair with the MitraClip. *Neth Heart J*. 2010;18:606.
3. Van den Branden BJ, Post MC, Swaans MJ, et al. Percutaneous mitral valve repair using the edge-to-edge technique in a high-risk population. *Neth Heart J*. 2010;18:437–43.
4. Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve disease in patients with congenitally corrected transposition of the great arteries. *Circulation*. 1998;98:997–1005.

